FierceBiotech

New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis

HUMIRA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. HUMIRA has been shown to reduce the rate of progression of ...
FierceBiotech

HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings Fr

HUMIRA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. HUMIRA has been shown to reduce the rate of progression of ...
Monthly Prescribing Reference

Anti-TNF Agents Go Head-to-Head in RA Superiority Study

man hands gout arthritis The trial compares short- and long-term outcomes of Cimzia and Humira in RA WASHINGTON, DC—Data from a head-to-head superiority trial comparing Cimzia (certolizumab pegol) and ...
Monthly Prescribing Reference

Tofacitinib Goes Head-to-Head with Adalimumab in Rheumatoid Arthritis Study

Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate. The non-inferiority study found ...
Medscape

Pediatric Crohn's Disease: Adalimumab Plus Methotrexate Offers Strong Benefit

Findings from a landmark clinical trial in pediatric Crohn's disease show a clear benefit of adding methotrexate to treatment with the tumor necrosis factor inhibitor (TNFi) adalimumab (Humira), but ...
Business Insider

AbbVie's HUMIRA® (Adalimumab) Approved by Health Canada to Treat Pediatric Patients with Chronic Non-infectious Anterior Uveitis

MONTREAL, Feb. 20, 2019 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA® (adalimumab) for the treatment of ...